These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28131527)

  • 1. Corrigendum to 'Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer' [Gynecol. Oncol. 141 (2016) 199-205].
    Cox Bauer CM; Greer DM; Kram JJF; Kamelle SA
    Gynecol Oncol; 2017 Mar; 144(3):649. PubMed ID: 28131527
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer.
    Cox Bauer CM; Greer DM; Kram JJF; Kamelle SA
    Gynecol Oncol; 2016 May; 141(2):199-205. PubMed ID: 26905210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort.
    Tuomi T; Pasanen A; Leminen A; Bützow R; Loukovaara M
    Gynecol Oncol; 2017 Mar; 144(3):510-514. PubMed ID: 28069268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival" [Gynecol. Oncol. 141 (2016) 421-427].
    Boothe D; Orton A; Odei B; Stoddard G; Suneja G; Poppe MM; L Werner T; Gaffney DK
    Gynecol Oncol; 2016 Dec; 143(3):690-691. PubMed ID: 27726921
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.
    AlHilli MM; Podratz KC; Dowdy SC; Bakkum-Gamez JN; Weaver AL; McGree ME; Keeney GL; Cliby WA; Mariani A
    Gynecol Oncol; 2013 Oct; 131(1):103-8. PubMed ID: 23845691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "Adjuvant and first line chemotherapy use for endometrial cancer" [Gynecol. Oncol. Rep. 41 (2022) 101002].
    Knisely A; Huang Y; Li Y; Prabhu VS; Wright JD
    Gynecol Oncol Rep; 2023 Apr; 46():101112. PubMed ID: 37082519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum to "Co-existent abdominoperitoneal tuberculosis with endometrial cancer: A diagnostic and surgical challenge" [Gynecol. Oncol. Rep. 37 (2021) 100848].
    Ashraf M; Goh WA; Tan EMX; Nadarajah R
    Gynecol Oncol Rep; 2021 Nov; 38():100861. PubMed ID: 34977315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of nomograms designed to predict lymphatic dissemination in patients with early-stage endometrioid endometrial cancer: a multicenter study.
    Bendifallah S; Canlorbe G; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Huguet F; Cortez A; Daraï E; Ballester M
    Am J Obstet Gynecol; 2015 Jan; 212(1):56.e1-7. PubMed ID: 24983678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphovascular space invasion and positive pelvic lymph nodes are independent risk factors for para-aortic nodal metastasis in endometrioid endometrial cancer.
    Solmaz U; Mat E; Dereli ML; Turan V; Tosun G; Dogan A; Sanci M; Ozdemir IA; Pala EE
    Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():63-7. PubMed ID: 25638600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
    Santin AD; Filiaci V; Bellone S; O'Cearbhaill R; Ratner ES; Mathews CA; Cantuaria G; Gunderson CC; Rutledge T; Buttin BM; Lankes HA; Birrer MJ
    Gynecol Oncol Rep; 2020 Aug; 33():100590. PubMed ID: 32885014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591].
    Frumovitz M; Burzawa JK; Byers LA; Lyons YA; Ramalingam P; Coleman RL; Brown J
    Gynecol Oncol; 2016 Oct; 143(1):224. PubMed ID: 27477189
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Fox E; McCuaig J; Demsky R; Shuman C; Chitayat D; Maganti M; Murphy J; Rosen B; Ferguson S; Randall Armel S
    Gynecol Oncol; 2017 May; 145(2):409. PubMed ID: 28256319
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.
    Barber EL; Rutstein SE; Miller WC; Gehrig PA
    Gynecol Oncol; 2016 Aug; 142(2):380. PubMed ID: 27264077
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to 'Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
    Gynecol Oncol; 2017 Feb; 144(2):448. PubMed ID: 28089052
    [No Abstract]   [Full Text] [Related]  

  • 15. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement.
    Boren T; Lea J; Kehoe S; Miller DS; Richardson D
    Gynecol Oncol; 2012 Oct; 127(1):43-6. PubMed ID: 22713294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Naumann RW; Coleman RL; Brown J; Moore KN
    Gynecol Oncol; 2020 Feb; 156(2):512-513. PubMed ID: 31859001
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "HPV vaccines-A review of the first decade" [Gynecol. Oncol. 146 (2017) 196-204].
    Harper DM; DeMars LR
    Gynecol Oncol; 2017 Nov; 147(2):489. PubMed ID: 28844538
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Indications for and complications of transfusion and the management of gynecologic malignancies" [Gynecol. Oncol. 146 (2017) 416-426].
    Cybulska P; Goss C; Tew WP; Parameswaran R; Sonoda Y
    Gynecol Oncol; 2018 Jan; 148(1):235. PubMed ID: 29203176
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA
    Gynecol Oncol; 2019 Jan; 152(1):220. PubMed ID: 30360899
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to 'Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study' [Gynecol. Oncol. 143 (2016) 77-82].
    Kong TW; Lee JD; Son JH; Paek J; Chun M; Chang SJ; Ryu HS
    Gynecol Oncol; 2017 Jan; 144(1):228. PubMed ID: 27890281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.